Plain-English peptide research. Affiliate links are disclosed.

Sermorelin

Also cited in the literature as GRF (1-29)

A short copy of the body's own growth-hormone-releasing hormone. It was once sold as a medicine for testing growth hormone in children.

Regulatory status: Not licensed as a medicine in the United Kingdom. It holds no MHRA marketing authorisation, has no approved indication, and is not approved for human or animal use.

Illustration of peptide chains and cell-surface receptors

Hormone & signalling research

Research stage: Historic licensed diagnostic use overseas; no current authorisation

Cells
Animal studies
Human trials

The research pathway — not every compound has reached human trials. Illustrations are simplified, not study results.

What it is

Sermorelin is a laboratory-made copy of the first 29 amino acids of growth-hormone-releasing hormone, the signal the brain uses to tell the pituitary gland to release growth hormone.

How researchers think it works

Studies found that sermorelin acted on the same receptor as the natural hormone, prompting the pituitary gland to release stored growth hormone rather than adding hormone from outside.

What has research seen in people?

Human studies used it mainly as a test of whether the pituitary gland could release growth hormone, and it was once sold for exactly that purpose.

Small studies in older adults reported short-term rises in growth hormone and IGF-1 readings, but not improvements in health, strength or body composition.

The record is small and dated, and no current UK licence exists.

Where this material is listed

For laboratory research use only. Not a medicine and not for human or animal use.

Veritide does not sell or supply anything. This links to a third-party UK laboratory supplier; we may earn a commission if you buy through it, at no extra cost to you. Materials are sold for laboratory research use only and are not licensed medicines.

What studies have found

  • Published clinical work from the 1990s used it as a test of whether the pituitary gland could release growth hormone, and it was marketed for that purpose in the United States before being discontinued.
  • Small studies in older adults reported short-term rises in growth hormone and IGF-1 markers. Researchers did not report long-term health outcomes.

What we still do not know

  • The human record is small, mostly decades old, and focused on short-term hormone measurements rather than whether people were healthier.
  • The product that once held a licence was withdrawn from the market for commercial reasons, and no current licence exists in the UK.

Sources

Related profiles

Retatrutide

Triple incretin receptor agonist

An experimental peptide that acts on three hormone receptors. Researchers studied it in phase 2 trials involving weight and blood sugar.

Mazdutide

Dual GLP-1 / glucagon receptor agonist

An experimental peptide based on a natural gut hormone. Researchers studied it mainly in phase 2 and phase 3 trials in China.

BPC-157

Synthetic pentadecapeptide

A laboratory-made peptide made of 15 amino acids. Almost all published research involved cells or rodents rather than people.